We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Subscribe To Our Newsletter & Stay Updated